Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT
- PMID: 29808926
- DOI: 10.1111/bjh.15407
Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT
Abstract
Allogeneic Haematopoietic Stem Cell Transplant (allo-HSCT) remains the only curative approach for Myelofibrosis (MF). Scarce information exists in the literature on the outcome and, indeed, management of those MF patients who relapse following transplant. We hereby report on the management and outcome of 202 patients who relapsed post allo-HSCT for MF.
Keywords: JAK inhibitors; allogeneic stem cell transplant; fibrosis; mylelofibrosis; relapse.
© 2018 British Society for Haematology and John Wiley & Sons Ltd.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources

